HAPLN1 and plasma cell myeloma: In addition, HAPLN1 was shown to have the properties of an oncogene contributing to an increased susceptibility to lung cancer (47), aggressiveness of hepatocellular carcinomas (48), and drug resistance to multiple myeloma (49).